Catopil25 mg

Catopil is an angiotensin-converting enzyme (ACE) inhibitor with the following FDA-approved and guideline-supported uses:

• Hypertension: Established first-line or add-on therapy for management of high blood pressure, used alone or in combination with other antihypertensive agents (e.g., thiazide diuretics).
• Heart failure: Approved adjunct therapy (usually combined with diuretics and, where appropriate, digitalis) to improve symptoms and reduce mortality in patients with reduced ejection fraction.
• Left ventricular dysfunction after myocardial infarction: Approved to improve survival in clinically stable patients with left ventricular dysfunction following a heart attack.
• Diabetic nephropathy: Approved for patients with type 1 diabetes and established nephropathy (proteinuria greater than 500 mg/day) to slow progression of kidney disease.

Guideline bodies also support use of Catopil and other ACE inhibitors as part of broader cardiovascular risk reduction in select high-risk patients, but this should be individualized by a physician.

Each tablet contains Captopril as the active pharmaceutical ingredient, commonly available in strengths of 12.5 mg, 25 mg, and 50 mg. Tablets also contain standard pharmaceutical excipients such as microcrystalline cellulose, lactose, starch, and stearic acid, which may vary by manufacturer.

Catopil is an orally active angiotensin-converting enzyme (ACE) inhibitor. It was one of the first ACE inhibitors developed and is distinguished chemically by a sulfhydryl group, which is linked to some of its unique adverse effects (such as taste disturbance and skin rash).

Catopil is used in the management of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy. It works by relaxing blood vessels, which lowers blood pressure and reduces the workload on the heart.

Catopil belongs to the therapeutic class of Angiotensin-Converting Enzyme (ACE) Inhibitors, a group of medicines used mainly for cardiovascular and renal indications.

Mechanism

Captopril competitively inhibits angiotensin-converting enzyme (ACE), which blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This reduces peripheral vascular resistance and blood pressure, decreases aldosterone secretion (leading to modest potassium retention), and increases plasma renin activity through loss of negative feedback.

Pharmacokinetics

• Absorption: Rapidly absorbed orally, with at least 75% bioavailability; food reduces absorption by about 30–40%, so it is usually taken on an empty stomach.
• Onset/Duration: Antihypertensive effect begins within 15–60 minutes; duration is dose-dependent.
• Metabolism/Excretion: Partially metabolized in the liver; eliminated primarily via the kidneys, largely unchanged.
• Half-life: Approximately 2 hours in patients with normal renal function; prolonged in renal impairment.

Catopil tablets should be swallowed with water, preferably one hour before meals, since food can reduce absorption. Doses are usually given two to three times daily as directed by the physician. Do not stop taking Catopil suddenly without medical advice, even if you feel well, as this may worsen the underlying condition.

Catopil has the following well-documented, clinically significant drug interactions:

• Potassium-sparing diuretics, potassium supplements, or salt substitutes: Increased risk of hyperkalemia; combination requires caution and monitoring of serum potassium.
• NSAIDs (e.g., ibuprofen, indomethacin): May reduce the antihypertensive effect of Catopil and increase the risk of renal impairment, particularly in elderly or volume-depleted patients.
• Lithium: Catopil can reduce lithium clearance, increasing serum lithium levels and risk of toxicity; concurrent use requires monitoring of lithium levels.
• Other diuretics: May cause excessive drop in blood pressure, especially with the first dose; a lower starting dose is recommended.
• Aliskiren or angiotensin receptor blockers (ARBs): Dual blockade of the renin-angiotensin system with Catopil increases the risk of hyperkalemia, hypotension, and renal impairment; combination with aliskiren is contraindicated in patients with diabetes (see Contraindications).
• Probenecid: May reduce renal clearance of Catopil, increasing its plasma levels.

Common and important side effects of Catopil include:

• Common: Dry, persistent, non-productive cough; taste disturbance (metallic taste or loss of taste); skin rash; dizziness; headache; mild increase in serum potassium.
• Less common but important: First-dose hypotension, especially in volume-depleted patients; proteinuria.
• Rare but serious: Angioedema (swelling of face, lips, tongue, or throat — requires immediate discontinuation and medical attention); neutropenia or agranulocytosis (more common with renal impairment or collagen vascular disease); acute renal failure (especially with bilateral renal artery stenosis); cholestatic jaundice progressing rarely to hepatic necrosis.

Patients should seek prompt medical attention for swelling of the face/throat, difficulty breathing, signs of infection (fever, sore throat), or yellowing of the skin/eyes while taking Catopil.

Boxed Warning: Fetal Toxicity

Catopil can cause injury and death to the developing fetus when used during the second and third trimesters of pregnancy. Catopil must be discontinued as soon as pregnancy is detected, and an alternative agent should be used if continued antihypertensive therapy is needed. Catopil is contraindicated in pregnancy.

Lactation

Catopil is excreted into breast milk in small amounts. Because of the potential for adverse effects in a nursing infant, Catopil should be used during breastfeeding only if clearly needed and the potential benefit justifies the potential risk; a physician should be consulted, and the infant should be monitored for signs of hypotension.

The following precautions apply to use of Catopil:

• Hypotension: Symptomatic hypotension, particularly after the first dose, may occur in volume- or salt-depleted patients (e.g., those on diuretics); correct volume depletion before starting Catopil where possible.
• Renal impairment / bilateral renal artery stenosis: Catopil can cause acute renal failure in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney; renal function should be monitored, especially in patients with pre-existing kidney disease.
• Hyperkalemia: Risk is increased with renal impairment, diabetes, or concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes (see Interactions).
• Neutropenia/agranulocytosis: Rare, but risk is higher in patients with renal impairment, especially those with collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma); periodic monitoring of white blood cell counts may be advised by the physician in these patients.
• Angioedema: Can occur at any time during treatment; if swelling of the face, lips, tongue, or throat occurs, discontinue Catopil immediately and seek emergency care.
• Cough: A persistent dry cough is a known class effect of Catopil and other ACE inhibitors; it is not dangerous but is a common reason patients discontinue therapy — discuss with a physician rather than stopping abruptly on your own.
• Surgery/anesthesia: Catopil may increase the risk of hypotension during major surgery or anesthesia; inform the treating physician if you are taking Catopil.

Overdose of Catopil may cause severe hypotension, shock, electrolyte disturbances, and acute renal failure. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center right away. Treatment is supportive, generally provided in a hospital setting (for example, intravenous fluids for hypotension); do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Catopil has been used in children under close specialist supervision with individualized, weight-based dosing, but safety and efficacy have not been formally established in neonates and infants, who may be more susceptible to hypotension and oliguria; use in this age group is generally reserved for specialist care with close monitoring.

Elderly

Elderly patients may be more sensitive to the blood-pressure-lowering effects of Catopil and are more likely to have reduced renal function; a lower starting dose and careful monitoring of renal function and blood pressure are recommended.

Renal Impairment

Dose reduction and monitoring are required, as Catopil is primarily eliminated by the kidneys (see Dosage and Administration).

Hepatic Impairment

No specific dose adjustment is established, but Catopil should be used cautiously given rare reports of hepatic injury.

Catopil is generally used long-term for chronic conditions such as hypertension, heart failure, and diabetic nephropathy, under ongoing physician supervision. Duration of therapy after myocardial infarction is determined by the treating physician based on clinical response. Do not stop Catopil without medical advice, even if blood pressure appears normal, as this may reflect the medicine working rather than the underlying condition being resolved.

Captopril is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor.

Captopril inhibits angiotensin-converting enzyme, blocking conversion of angiotensin I to angiotensin II. This reduces vasoconstriction and aldosterone-mediated sodium and water retention, resulting in lowered blood pressure and reduced cardiac workload.

D

Catopil may be used in pediatric patients with hypertension under specialist supervision, using individualized, weight-based dosing started at the lowest possible dose with careful titration and monitoring of blood pressure and renal function. Safety and efficacy in neonates and infants have not been formally established, and this age group is at increased risk of prolonged and profound hypotension; use in neonates and infants should be limited to specialist care with intensive monitoring.